- Home
- TC vs PPCB Comparison
TC vs PPCB Comparison
Compare TC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- PPCB
- Stock Information
- Founded
- TC 2010
- PPCB 2007
- Country
- TC China
- PPCB Australia
- Employees
- TC N/A
- PPCB N/A
- Industry
- TC Business Services
- PPCB
- Sector
- TC Consumer Discretionary
- PPCB
- Exchange
- TC Nasdaq
- PPCB Nasdaq
- Market Cap
- TC 25.0M
- PPCB 20.4M
- IPO Year
- TC 2018
- PPCB N/A
- Fundamental
- Price
- TC $15.38
- PPCB $1.26
- Analyst Decision
- TC
- PPCB
- Analyst Count
- TC 0
- PPCB 0
- Target Price
- TC N/A
- PPCB N/A
- AVG Volume (30 Days)
- TC 15.9K
- PPCB 337.6K
- Earning Date
- TC 12-16-2025
- PPCB 09-30-2025
- Dividend Yield
- TC N/A
- PPCB N/A
- EPS Growth
- TC N/A
- PPCB N/A
- EPS
- TC N/A
- PPCB N/A
- Revenue
- TC $5,115,721.00
- PPCB N/A
- Revenue This Year
- TC N/A
- PPCB N/A
- Revenue Next Year
- TC N/A
- PPCB N/A
- P/E Ratio
- TC N/A
- PPCB N/A
- Revenue Growth
- TC N/A
- PPCB N/A
- 52 Week Low
- TC $9.20
- PPCB $1.25
- 52 Week High
- TC $39.00
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- TC 56.46
- PPCB N/A
- Support Level
- TC $14.50
- PPCB N/A
- Resistance Level
- TC $16.00
- PPCB N/A
- Average True Range (ATR)
- TC 1.49
- PPCB 0.00
- MACD
- TC -0.32
- PPCB 0.00
- Stochastic Oscillator
- TC 31.10
- PPCB 0.00
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.